Clearside Biomedical, Inc.
CLSD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | -59.1% | -78.9% | 661.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $2 | $0 |
| % Margin | 100% | 82.9% | 89.4% | 51.3% |
| R&D Expenses | $3 | $2 | $4 | $4 |
| G&A Expenses | $4 | $2 | $3 | $3 |
| SG&A Expenses | $4 | $2 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $7 | $4 | $7 | $7 |
| Operating Income | -$7 | -$4 | -$5 | -$7 |
| % Margin | -3,502.5% | -725.2% | -223.4% | -2,336.3% |
| Other Income/Exp. Net | $1 | -$1 | -$2 | -$0 |
| Pre-Tax Income | -$6 | -$4 | -$8 | -$7 |
| Tax Expense | $0 | $0 | $1 | $0 |
| Net Income | -$6 | -$4 | -$8 | -$7 |
| % Margin | -2,971.1% | -913.6% | -352.9% | -2,387.6% |
| EPS | -1.14 | -0.87 | -1.65 | -1.445 |
| % Growth | -31% | 47.3% | -14.2% | – |
| EPS Diluted | -1.14 | -0.87 | -1.65 | -1.445 |
| Weighted Avg Shares Out | 5 | 5 | 5 | 5 |
| Weighted Avg Shares Out Dil | 5 | 5 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$2 | -$5 | -$5 |
| % Margin | -1,650.7% | -335.2% | -203.9% | -1,519% |